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Medicine I, Katholisches Klinikum Mainz, An der Goldrube 11, 55131 Mainz, Germany; 19Respiratory Department, Ramón y Cajal Hospital, Universidad de Alcala, IRYCIS, Ctra.
Colmenar Viejo, km. 9, 100, 28034 Madrid, Spain; 20Emergency Medicine, University of Helsinki, Department of Emergency Medicine and Services, Helsinki University Hospital,
Tukholmankatu 8A, 00290 Helsinki, Finland; 21Department of Internal Medicine, Medical Mission Hospital, Academic Teaching Hospital of the Julius-Maximilian University of
Wuerzburg, Josef-Schneider-Strasse 2, 97080 Wuerzburg, Germany; 22Department of Emergency Medicine, Santa Maria della Misericordia Hospital, Piazzale Santa Maria della
Misericordia 15, 33100 Udine, Italy; 23Department of Internal Medicine II, Division of Pneumology, University Medical Center Regensburg, Franz-Josef-Strauss-Allee 11, 93053
Regensburg, Germany; 24Department of Cardiology, General Hospital ‘Asklepeion Voulas’, Leof. Vasileos Pavlou 1, 166 73 Athens, Greece; 25Kliniken Maria Hilf, Klinik für
Pneumologie, Krankenhaus St. Franziskus, Viersener Str. 450, 41063 Mönchengladbach, Germany; 26Department of Medicine, Keski-Suomi Central Hospital and University of
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Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE,




We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management
trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of
(i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities.
Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for
>_3 months. The primary outcome was symptomatic recurrent venous thromboembolism (VTE) or PE-related
death within 3 months of enrolment. An interim analysis was planned after the first 525 patients, with prespecified
early termination of the study if the null hypothesis could be rejected at the level of a = 0.004 (<6 primary out-
come events). From May 2014 through June 2018, consecutive patients were enrolled in seven countries. Of the
525 patients included in the interim analysis, three (0.6%; one-sided upper 99.6% confidence interval 2.1%) suffered
symptomatic non-fatal VTE recurrence, a number sufficiently low to fulfil the condition for early termination of the
trial. Major bleeding occurred in 6 (1.2%) of the 519 patients comprising the safety population. There were two
cancer-related deaths (0.4%).
...................................................................................................................................................................................................
Conclusion Early discharge and home treatment with rivaroxaban is effective and safe in carefully selected patients with acute
low-risk PE. The results of the present trial support the selection of appropriate patients for ambulatory treatment
of PE.
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Introduction
Acute pulmonary embolism (PE) is a frequent cause of cardiovascular
mortality worldwide1 and represents a major threat for ageing popu-
lations. As PE is characterized by a wide spectrum of severity, risk
assessment is mandatory to define the appropriate management
strategy.2 The current guidelines of the European Society of
Cardiology (ESC) propose a stepwise risk stratification approach,
using a combination of clinical findings, imaging, and biochemical
markers, to distinguish between patients with high, intermediate, and
low risk of an early adverse outcome.3 In this regard, one of the most
challenging tasks is to identify, within the large group of normotensive
and apparently stable patients,4 those whose risk is ‘sufficiently low’
to permit early discharge and ambulatory treatment. Such an ap-
proach, if shown to be safe, may minimize early complications related
to hospitalization5 and have an impact on healthcare costs6 as well as
on patient satisfaction and quality of life.7,8
In the era of the vitamin K antagonists (VKAs), a number of cohort
studies and two randomized controlled trials investigated whether
ambulatory treatment of acute PE might be feasible and safe.8–12
These studies, most of which included rather small patient popula-
tions and were conducted in single countries, used different sets of
clinical, laboratory, and social criteria to define eligibility for early dis-
charge. As a consequence of these limitations, the optimal criteria
and treatment regimen to support early discharge strategies for
patients with PE have remained controversial. In a recently published
real-life European study, as few as 7% of patients with acute low-risk
PE were discharged ‘immediately’ after diagnosis and more than 50%
stayed in hospital for more than 5 days.13
Recent developments may help to revisit this attitude. Non-
vitamin K antagonist oral anticoagulants (NOACs) are increasingly
becoming the standard of care for treatment of acute PE. Two of
these agents, the factor Xa inhibitors apixaban and rivaroxaban, can
be administered as a single oral drug regimen, obviating the need for
initial parenteral treatment with low-molecular-weight heparin
(LMWH) and thus facilitating the early transition from hospital to am-
bulatory care.14 In parallel, risk-adapted management strategies con-
tinue to evolve. In this latter context, the results of a recent meta-
analysis including 21 studies with more than 3000 patients indicated
that the presence of right ventricular (RV) dysfunction on admission
may be associated with an increased risk of early PE-related adverse
events and death in patients classified into the low-risk category sole-
ly on the basis of clinical parameters.15 These results reinforce the
concept that the functional status of the RV should be integrated into
the process of patient selection.3,16
The Home Treatment of Patients with Low-Risk Pulmonary
Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE)
trial was designed to address the ongoing change of paradigm in PE
care. Specifically, we investigated whether early discharge and ambu-
latory treatment with the oral factor Xa inhibitor rivaroxaban is ef-
fective and safe in patients with acute low-risk PE selected on the
basis of clinical criteria as well as the absence of RV dysfunction on































































































admission. The present report focuses on the results of the prespeci-
fied interim analysis, which was performed after recruitment and
3-month evaluation of 525 patients corresponding to 50% of the ini-
tially planned intention-to-treat (ITT) trial population.
Methods
Study design and participants
The rationale and study design of HoT-PE have been published previous-
ly.17 HoT-PE (EudraCT Nr. 2013-001657-28) is a prospective multicentre
single-arm investigator-initiated Phase 4 interventional trial sponsored by
the University Medical Centre Mainz, Germany, and supported by public
funding. In addition, the sponsor obtained the study drug and a grant from
the market authorization holder of rivaroxaban (Bayer AG). The authors
were entirely responsible for the design and conduct of the study, statis-
tical analysis, interpretation of results, and drafting of the manuscript. The
sponsor’s academic research organization was responsible for data col-
lection and monitoring at the participating sites in Germany; in the other
participating countries, this task was performed by an international clinical
research organization appointed by the sponsor. The institutional ethics
review board of each participating site approved the study protocol and
two amendments, all of which are available as Supplementary online ma-
terial. All patients provided written informed consent for participation in
the study. An independent Data and Safety Monitoring Board periodically
reviewed the study.
The inclusion and exclusion criteria are listed in the Supplementary on-
line material; their rationale has been explained previously.6 Briefly,
patients were eligible for inclusion if they were 18 years of age or older
and had objectively confirmed acute PE; in addition, evidence of absence
of RV enlargement or dysfunction [RV/left ventricle (RV/LV) ratio >_ 1.0],
and of free-floating thrombi in the right atrium or ventricle, was required
by echocardiography or computed tomographic pulmonary angiography
(CTPA). The majority of the exclusion criteria corresponded to items
adapted from the Hestia management study.11 More specifically, patients
were excluded if they had haemodynamic instability at presentation;
mechanical or pharmacological reperfusion, or placement of a cava filter;
active bleeding or known significant bleeding risk; need for supplemental
oxygen administration; chronic treatment with anticoagulant drugs; pain
requiring parenteral administration of analgesic agents; other medical
conditions requiring hospitalization; non-compliance or inability to ad-
here to the treatment or the follow-up visits, or lack of a family environ-
ment or support system; and contraindications to rivaroxaban as defined
in the summary of product characteristics of the drug.
Treatment
Treatment with an approved parenteral or oral anticoagulant [unfractio-
nated heparin (UFH), LMWH, fondaparinux, rivaroxaban, or apixaban]
was allowed before enrolment, but should have been started no later
than 3 h after confirmation of PE. After enrolment in the study, patients
received the first dose of rivaroxaban 2 h or less before the time that the
next subcutaneous injection of LMWH or fondaparinux (or oral dose of
rivaroxaban or apixaban) would have been due, or at the time of discon-
tinuation of intravenous UFH.
The rivaroxaban dosage scheme was based on the label of the mar-
keted product for the treatment of acute PE; it consisted of 15 mg twice
daily for the first three weeks followed by 20 mg once daily for at least
three months. Reduction of the maintenance dose to 15 mg once daily
was possible at the discretion of the treating physician for patients with
creatinine clearance below 50 mL/min, if the individual risk for bleeding
was deemed to outweigh the risk for recurrent venous thromboembolism
(VTE). The trial protocol mandated that patients be discharged from the
hospital within 48 h of initial presentation for PE; it tolerated up to two
nights of hospital stay.
Follow-up and study outcomes
All patients were followed for 3 months with a final on-site visit scheduled
90 (±7) days after enrolment. A 24-h emergency telephone number was
provided, and patients received instructions on how to behave if they
noticed symptoms suggestive of VTE recurrence or bleeding.
The primary efficacy outcome was symptomatic recurrent VTE, or PE-
related death within 3 months of enrolment. Recurrent PE was confirmed
using the same diagnostic procedure(s) as the initial event, and defined as
at least one of the following: (i) a new intraluminal filling defect on CTPA
or pulmonary angiography; (ii) a new perfusion defect involving at least
75% of a segment with normal ventilation on lung scan; (iii) a non-
diagnostic lung scan accompanied by evidence of (new) deep vein throm-
bosis on ultrasonography; new PE (fresh thrombi) at autopsy. The safety
outcomes included major bleeding (defined by the criteria of the
International Society on Thrombosis and Haemostasis),18 clinically rele-
vant non-major bleeding, and serious adverse events. Secondary efficacy
outcomes included all-cause mortality and the number of rehospitaliza-
tions due to PE or to a bleeding event within three months. All efficacy
and safety outcomes were adjudicated by an independent clinical events
committee; a detailed description of all outcome measures has been pub-
lished before.17
Sample size calculation and criteria for early
study termination
The null hypothesis (H0) that P >_0.03 (P being the probability of recurrent
VTE or PE-related death within 3 months) was tested against the alterna-
tive hypothesis (H1) that P < 0.03, using a binomial test (two-stage adap-
tive design based on an O’Brien Fleming design) and assuming a 3-month
symptomatic VTE recurrence rate of 1.7%. A total of 1050 patients were
required to provide 80% power to reject H0 at an overall significance
level a <_ 0.05. The point estimate (1.7%) and the upper margin (3%) of
the 3-month symptomatic VTE recurrence rate were chosen based on
studies dating back to the VKA era.19 Moreover, the rate of 1.7% is also
similar to the 3-month rate observed in the EINSTEIN-PE trial which
compared rivaroxaban to VKA anticoagulation for the treatment of acute
PE.20 An interim analysis was planned after enrolment and 3-month evalu-
ation of the first 525 patients in the ITT population, with the objective of
early termination of the study if H0 could be rejected at the level of
a = 0.004; this corresponded to less than six symptomatic or fatal recur-
rent VTE events.
Statistical analysis
The primary and secondary outcome analyses were performed in the
ITT population, which included all patients who signed the informed con-
sent. Safety analysis was conducted in the safety population, including all
patients who received at least one dose of study drug. Per-protocol ana-
lysis was carried out as a sensitivity analysis for the primary outcome,
including all patients who received at least one dose of study drug and ful-
filled the protocol requirements for early discharge from the hospital. A
sensitivity analysis was planned by imputing missing data for the primary
outcome according to the worst-case principle assuming that the primary
outcome had occurred. Details regarding the Statistical Analysis Plan and
the interim analysis have been published previously17 and are provided in
the study protocol available in the Supplementary online material.




























































From May 2014 through June 2018, a total of 2854 patients diagnosed
with acute PE were screened for enrolment at 49 centres in seven
countries. Sites in Germany were initiated in 2014 and 2015, whereas
centres in other European countries were initiated starting in 2016.
Figure 1 displays the screening, selection, and enrolment process.
Of 525 patients included in the interim analysis of the ITT population,
240 (45.7%) were women and the mean age was 57 (range 18–90)
years. Their baseline characteristics are shown in Table 1. The median
duration between the onset of symptoms and PE diagnosis was 4
[interquartile range (IQR) 2–9] days. The most frequent symptom
was dyspnoea (61.0% of patients), followed by pleuritic pain (38.5%),
cough (21.1%), retrosternal pain (21.0%), fever (7.6%), haemoptysis
(5.1%), and syncope (2.7%). Unilateral leg pain was present in 24.2%
and unilateral oedema in 15.1% of patients.
The diagnosis of acute PE was confirmed based on the results of
CTPA in 463 (88.2%) patients, ventilation-perfusion lung scan in 55
(10.5%), and pulmonary angiography in 33 (6.3%) patients, alone or in
combination. Echocardiography was performed in 447 (85.1%)
patients. A total of 388 patients underwent both CTPA and echocar-
diography; of 137 patients in whom the RV/LV ratio was assessed and
reported by both methods, four (2.9%) had a ratio of >_1.0 on CTPA
but were included in the trial because all echocardiographic parame-
ters (including the RV/LV ratio) were normal. Compression ultra-
sound of the lower extremities (not mandated by the protocol) was
performed in 415 (79.0%) patients, and deep vein thrombosis was
detected in 214 (40.8% of the total study population).
Anticoagulation during and after
hospitalization for index PE
Before enrolment, initial anticoagulation was given to 505 (96.2%)
patients and consisted of LMWH in 344 (65.5%) patients (Table 2).
As already mentioned, the trial protocol mandated discharge from
the hospital within 48 h of presentation, permitting up to two nights
of hospital stay for patients who had been admitted early after mid-
night. In compliance with the protocol, 502 (96.0%; 2 missing values)
patients were hospitalized for up to two nights; of these, 61 (11.7%)
were discharged directly and 219 (41.9%) were hospitalized for one
night. The median length of hospitalization was 34 (IQR 23–47) h,
and the median time from PE diagnosis to discharge 31 h. Eleven
(2.1%) patients required prolonged hospitalization due to early ad-
verse events. These included acute infection (n = 5), elevation of
troponin (n = 2), cancer-related complications (n = 2), fever (n = 1),
and removal of an external bone fixator (n = 1).
After enrolment, 519 (98.9%) patients received at least one dose
of rivaroxaban (safety population). Initial anticoagulation with rivar-
oxaban 15 mg twice daily was given over a mean period of 21 [stand-
ard deviation (SD) 3] days. Rivaroxaban was given at the standard
maintenance dosage of 20 mg once daily over a mean period of 68
(SD 13) days; the reduced dosage of 15 mg once daily was given to
four patients. Three patients unintentionally received supra-
therapeutic doses of rivaroxaban for 4, 11, and 32 days, respectively.
Primary efficacy outcome
The primary efficacy outcome of symptomatic recurrent VTE or PE-
related death within three months occurred in three [0.6%; one-
sided upper 99.6% confidence interval (CI) 2.1%; one-sided P-value
<0.0001] of the 525 patients of the ITT population (Table 3). All three
recurrent events presented as non-fatal PE (Table 4). Figure 2 depicts
the early stopping boundaries along with subject-by-subject account-
ing of the event rate, thus visually providing the justification for early
termination of the study after 50% of the initially planned patient
population based on the predefined interim analysis. According to
the prespecified worst case scenario analysis, the primary efficacy
outcome might have occurred in two further patients with
Figure 1 Flow diagram of the screening, selection, and enrolment process. PE, pulmonary embolism; VKA, vitamin K antagonist.






































..incomplete follow-up, amounting to a theoretical rate of 0.95% (one-
sided upper 95% CI 2.0%; one-sided P-value = 0.0015).
Of the 497 patients included in the per-protocol population, the
primary outcome occurred in two (0.4%; one-sided upper 95% CI
1.3%; one-sided P-value < 0.0001). A similar rate (0.4%) was
observed in patients who were discharged early and received a com-
plete 3-month treatment of rivaroxaban (n = 482).
Safety and secondary efficacy outcomes
The safety and secondary efficacy outcomes are shown in Table 3. Six
(1.2%, two-sided 95% CI 0.4–2.5%) of 519 patients in the safety popu-
lation had a major bleeding episode. Table 4 summarizes the time to
occurrence and the characteristics of these events. Clinically relevant
non-major bleeding occurred in 31 (6.0%; two-sided 95% CI 4.1–
8.4%) of 519 patients included in the safety population. Serious ad-
verse events occurred in 58 (11.2%; two-sided 95% CI 8.6–14.2%)
patients; a complete overview of the type and time of onset of these
events is provided in the Supplementary material online.
A total of 54 (10.3%) of 525 patients required either prolongation
of the initial hospital stay (n = 11) or rehospitalization (n = 43) due to
serious adverse events, which occurred a median of 14 (IQR 4–54)
days after the initial presentation. The median additional length of
hospital stay (including rehospitalizations) was 6 (IQR 3–9) days.
Twelve (2.3%) patients required rehospitalization due to suspected
VTE recurrence or bleeding, which was subsequently confirmed in 7
(1.3%) cases; Tables 3 and 4.
Two patients (0.4%; 95% CI 0.1–1.4%) died 46 days and 89 days
after enrolment due to complications of metastatic gynaecological
cancer and advanced mesothelioma, respectively. One further pa-
tient who had intracranial haemorrhage (Table 4) on Day 72 survived
the 3-month follow-up period but died 10 weeks after the event.
Discussion
We conducted an international multicentre single-arm Phase 4 man-
agement trial, designed to test whether early discharge and ambula-
tory treatment of patients with acute low-risk PE with rivaroxaban is
effective and safe. The study was terminated for efficacy after the pre-
defined interim analysis, which was performed after enrolment and
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of the study population
Variables Value Missing or
not tested
Patient demographics
Age (years), mean (SD; range) 56.7 (16.6; 18–90) 0
Age >80 years, n/N (%) 24/525 (4.6) 0
Women, n/N (%) 240/525 (45.7) 0
Caucasian, n/N (%) 517/525 (98.5) 0
Functional parameters and biochemical markers
Body mass index (kg/m2), median (IQR) 27.1 (24.2–30.5) 15
Systolic/diastolic blood pressure (mmHg), mean (SD) 137 (19)/80 (12) 1
Heart rate (b.p.m.), mean (SD) 78 (13) 0
Oxygen saturation (%), median (IQR) 97 (96–98) 18
Body temperature (C), mean (SD) 36.6 (0.6) 28
Respiratory rate (breaths per minute), median (IQR) 16 (15–18) 57
Creatinine clearance <50 mL/min, n/N (%) 29/525 (5.5) 0
Risk factors for pulmonary embolism and comorbidities
Oestrogen use, n/N (%) 81/520 (15.6) 5
Immobilization (for at least 3 days), n/N (%) 54/520 (10.4) 5
Previous deep vein thrombosis, n/N (%) 82/515 (15.9) 10
Previous pulmonary embolism, n/N (%) 39/521 (7.5) 4
Recent major surgery (past 30 days), n/N (%) 37/523 (7.1) 2
Recent major trauma (past 30 days), n/N (%) 23/524 (4.4) 1
Recent stroke (past 30 days), n/N (%) 0/524 (0) 1
Long travel (>4 h, past 30 days), n/N (%) 66/517 (12.8) 8
Active cancer, n/N (%) 32/518 (6.2) 7
Chronic obstructive pulmonary disease, n/N (%) 26/518 (5.0) 7
Chronic heart failure, n/N (%) 7/524 (1.3) 1
Coronary artery disease, n/N (%) 40/519 (7.7) 6
Arterial hypertension, n/N (%) 211/522 (40.4) 3
Simplified pulmonary embolism severity index >_1, n/N (%) 107/506 (21.1) 19
IQR, interquartile range; SD, standard deviation.














































..3-month follow-up of 50% of the initially planned patient population.
The rate of symptomatic recurrent VTE or PE-related death within 3
months was 0.6% (one-sided upper 99.6% CI 2.1%), thus permitting
the early rejection of the null hypothesis. Besides criteria including
the lack of serious comorbidities or conditions mandating hospitaliza-
tion, and the presence of a familial/social environment able to sup-
port ambulatory treatment, HoT-PE is the first management trial to
implement recent advances in our knowledge by defining the absence
of RV enlargement or dysfunction (reviewed and meta-analysed in
Ref. 15), and of free-floating thrombi in the right atrium or ventricle
on imaging, as a key exclusion criterion.
Acute PE is a potentially life-threatening acute cardiovascular syn-
drome. Therefore, the decision to discharge a patient within the first
hours following presentation may raise medical, ethical, and legal con-
cerns, which underline the importance of relying on validated criteria
for patient selection. Current guidelines3 support the use of two clin-
ical scores, the Pulmonary Embolism Severity Index (PESI) and its
simplified version (sPESI), for the identification of patients with low-
risk PE. In addition, the so-called Hestia criteria were proposed, aim-
ing to select candidates for early discharge by taking into account gen-
eral medical factors along with the patients’ social and family
supporting environment.11,12 Clinical criteria alone, however, may
not suffice to safely select patients with acute low-risk PE, since the
risk of early mortality and PE-related complications may be elevated,
despite a low clinical severity score, if RV dysfunction or intracardiac
thrombi are present.9,15 Today, assessment of the right ventricle by
imaging is a fast, uncomplicated process in most emergency depart-
ments.21 The HoT-PE trial therefore confirms that simple and easily
obtainable clinical and imaging parameters of severity can identify
patients at truly low risk of early PE-related complications.
The rates of efficacy and safety outcomes documented in HoT-PE
are generally in line with those reported in previous trials. Recurrent
symptomatic (non-fatal) VTE occurred within the first three months
in 0.6% of the patients enrolled in HoT-PE, compared with 2.0% of
those in the Hestia study and 0.6% in the Outpatient Treatment of
Pulmonary Embolism (OTPE) trial; both latter trials had used VKA
treatment.8 The incidence of major bleeding was 1.2% in HoT-PE vs.
0.7–1.8% in previous studies.8,11 In two large post-marketing studies
investigating the use of rivaroxaban in VTE, the rate of major bleeding
at three months ranged from 0.5% in a prospective Phase 4 study,
which included mostly patients with deep vein thrombosis, to2.0%
in the Dresden registry.22,23 The most frequent sites of major bleed-
ing in HoT-PE, notably gastrointestinal and uterine bleeding, are in
line with the results of previous trials on coagulation factor Xa inhibi-
tors.20,24 Clearly, any comparisons between the results of this and
previous studies should be interpreted with caution in view of the dif-
ferences in the patients’ characteristics and the anticoagulation strat-
egy followed.
HoT-PE is the first management study using a direct, NOAC which
does not require initial parenteral heparin anticoagulation and thus
offers the advantage of facilitated early discharge of patients at low
risk. The results of HoT-PE support the feasibility of this strategy,
....................................................................................................................................................................................................................
Table 2 Initial hospitalization and anticoagulant treatment
Variables Value Missing
Anticoagulant treatment before enrolment
Low-molecular-weight heparin, n/N (%) 344/525 (65.5) 0
Enoxaparin, n 234 0
Dalteparin, n 20 0
Nadroparin, n 17 0
Tinzaparin, n 39 0
Certoparin, n 30 0
Other or not specified, n 4 0
Unfractionated heparin, n/N (%) 43/525 (8.2) 0
Fondaparinux, n/N (%) 19/525 (3.6) 0
Rivaroxaban, n/N (%) 96/525 (18.3) 0
Apixaban, n/N (%) 3/525 (0.6) 0
No initial anticoagulation, n/N (%) 20/525 (3.8) 0
Hospitalization for index pulmonary embolism
Duration of hospitalization (h), median (IQR) 34 (23–47) 27 (exact time of admission
or discharge not stated)
Two nights or less in hospital 502/523 (96.0) 2
Prolonged initial hospitalization due to adverse events 11 —
Anticoagulant treatment after enrolment
Received the study medication, n 519 0
Rivaroxaban 15 mg twice daily for the initial therapy, mean duration (SD) 21 (3) 1
Rivaroxaban 20 mg once daily for the maintenance therapy, mean duration (SD) 68 (13) 1
Treatment not completed, n/N (%) 30/519 (5.8) 2
IQR, interquartile range; SD, standard deviation.
















































.since more than 95% of the study patients enrolled were hospitalized
for two nights or less, and 54% were either discharged immediately
or hospitalized for (only) one night after presentation. Long-term fol-
low-up focusing on 1-year survival of the patients included in HoT-PE
is still ongoing, and will also provide data on the quality of life, patient
satisfaction and, in selected countries, utilization of healthcare
resources.
Some limitations of our results need to be mentioned. First, it is
not possible to determine from an interventional management trial
like HoT-PE how many unselected patients with PE may fulfil our eli-
gibility criteria in clinical practice. The enrolment-to-screening ratio
did not represent a pre-defined measure of this trial and there was
significant heterogeneity among centres in the reported percentage
of screened patients who were ultimately enrolled. For example, in
25 of the 49 study sites, the reported enrolment rates exceeded
40%. Further, we cannot exclude the possibility that some eligible
patients may not have been screened for HoT-PE at some of the par-
ticipating study sites. Notwithstanding, the fact that overall only a mi-
nority, 20%, of the (reportedly) screened unselected patients with
acute PE were ultimately included in the trial, highlights the complex-
ity and need for individualization of management decisions concern-
ing early discharge and home treatment of PE. In this context, it can
be argued, based on the numbers shown in Figure 1, that relying on
the Hestia criteria alone might have increased the enrolment rate to
30% in our study, and that the reported inclusion rates in previous
studies using those clinical criteria were even higher, over 50%.11,12
However, beyond the medical rationale for additionally excluding RV
dysfunction or intracardiac thrombi as explained above, it needs to
pointed out that HoT-PE was performed in seven European coun-
tries with different healthcare systems, social infrastructure, geog-
raphy, and physicians’/patients’ preferences. This important aspect
should be taken into account when attempting comparisons of enrol-
ment feasibility with studies performed in a single country.
HoT-PE suggests that neither advanced age nor active cancer, two
of the ‘high-risk’ items included in sPESI, mandate by themselves a
prolonged hospital stay. Keeping in mind that the absolute numbers
of patients with these sPESI items were small and do not permit de-
finitive conclusions, these results are encouraging news with potential
medical and socioeconomic implications for ageing societies. The
strategy validated in HoT-PE may therefore be applicable to a large
number of patients and countries under real-life conditions, and that
it addresses the true medical need to shorten the duration of hospi-
talization for patients with acute low-risk PE.
Finally, no control arm with ‘conventional’ care was included in
our study. Such an arm might have been defined either as parenteral
heparin followed by VKA, or as hospitalization over several days cor-
responding to current practice in many European countries and hos-
pitals.13,25 The steering committee of HoT-PE decided against either
approach for the following reasons. First, high-quality Phase 3 trial
data demonstrating the efficacy and safety of PE treatment with
NOAC vs. LMWH followed by VKA had been published short be-
fore initiation of HoT-PE,20,26 and it was deemed unnecessary (and
perhaps also unethical) to reproduce existing robust evidence.
Second, from a historical perspective, the rapid evolution of care in
....................................................................................................................................................................................................................
Table 3 Study outcomes within 3 months of enrolment
Outcomes
Primary efficacy outcome
Recurrent venous thromboembolism or fatal PE, n/N (%; one-sided upper 99.6% CI) 3/525 (0.6; 2.1)
Recurrent PE, n (%; 95% CI) 3/525 (0.6; 0.1–1.7)
Recurrent deep vein thrombosis, n 0
Death related to PE, n 0
Safety outcomes
Major bleeding,a n/N (%; 95% CI) 6/519 (1.2; 0.4–2.5)
Clinically relevant bleeding, n/N (%; 95% CI) 31/519 (6.0; 4.1–8.4)
At least one serious adverse event, n/N (%; 95% CI) 58/519 (11.2; 8.6–14.2)
Secondary efficacy outcomes
Serious adverse events requiring prolonged initial hospitalization, or rehospitalization, n/N (%) 54/525 (10.3)
Time between initial presentation and first rehospitalization (days), median (IQR) 29 (7–56)
Duration of hospital stay due to serious adverse events (days), median (IQR, range) 6 (3–8)
Patients rehospitalized due to suspected recurrent PE or bleeding, n/N (%) 12/525 (2.3)
Pneumonia, n/N (%) 4/525 (0.8)
Recurrent PE, n/N (%) 2/525 (0.4)
Major bleeding, n/N (%) 4/525 (0.8)
Clinically-relevant-non-major bleeding, n/N (%) 1/525 (0.2)
Other, n/N (%) 1/525 (0.2)
Death of any cause within 3 months, n/N (%; 95% CI) 2/525 (0.4; 0.1–1.4)
Advanced cancer as cause of death, n 2
CI, confidence interval; IQR, interquartile range; PE, pulmonary embolism.
aAs defined by the criteria of the International Society on Thrombosis and Haemostasis.18

























the field deep vein thrombosis, which shifted to ambulatory treat-
ment as soon as effective and practical anticoagulation regimens be-
came available,27 was a strong argument against the feasibility of
randomizing patients with low-risk PE ‘back’ to longer hospitalization
periods, also considering that the safety or the approach chosen in
HoT-PE was constantly monitored by an independent data safety
monitoring board.
In conclusion, early discharge with continuation of anticoagulant
treatment at home was effective and safe in carefully selected patients
with acute PE. Patients were identified by clinical criteria of low risk
and the absence of RV dysfunction and of free-floating thrombi in the
right atrium or ventricle on admission, and received the standard
approved regimen of rivaroxaban for at least three months. The pre-
sent trial may have a clinically relevant impact on the selection of PE
patients for early discharge and ambulatory management, helping to
reduce in-hospital complications and rationalize the use of healthcare
resources.
Supplementary material
Supplementary material is available at European Heart Journal online.
....................................................................................................................................................................................................................













Female, 46 0 Recurrent PE 20 mg once
daily
29 4 Segmental recurrent PE
occurring during rivaroxa-
ban therapy. No haemo-
dynamic decompensation.
Rivaroxaban discontinuation
and switch to LMWH. No
further complications.
Male, 46 >_ 1 Recurrent PE 15 mg twice
daily
7 6 Segmental recurrent PE
occurring during rivaroxa-
ban therapy. No haemo-
dynamic decompensation.
The therapy with rivaroxa-
ban (15 mg twice daily)
was continued. No further
complications.
Female, 47 0 Recurrent PE 20 mg once
daily
75 — Segmental recurrent PE
occurring during rivaroxa-
ban therapy. No haemo-
dynamic decompensation.
Rivaroxaban discontinuation
and switch to LMWH; no
further complications.




12 1 Uterine bleeding. Rivaroxaban discontinuation
and switch to LMWH.




57 12 Haemorrhagic shock follow-
ing acute bleeding from in-
testinal diverticula.
Red blood cell concentrates;
rivaroxaban discontinu-
ation and switch to
LMWH. Subsequently, the








70 — Gastrointestinal bleeding
(onset 10 days before) and
anaemia.
—




72 — Uterine bleeding (onset 15
days before).
Rivaroxaban discontinuation.




57 6 Uterine bleeding (onset 20
days before).
Red blood cell concentrates;
rivaroxaban discontinu-
ation and switch to
LMWH.








died 69 days later.
PE, pulmonary embolism; LMWH, low-molecular-weight heparin; sPESI, simplified Pulmonary Embolism Severity Index.
aAs defined by the criteria of the International Society on Thrombosis and Haemostasis.18
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